Higher Plasma Level of Nampt Presaging Memory Dysfunction in Chinese Type 2 Diabetes Patients with Mild Cognitive Impairment
Authors:
- 6 June 2019
- journal article
- research article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 70 (1) , 303-314
Abstract
Background: In addition to glucose metabolism, adipocytokine Nicotinamide phosphoribosyltransferase (Nampt) has been proposed as a multifunctional protein involved in insulin resistance. Insulin resistance always occurs before the onset of type 2 diabetes mellitus (T2DM) and damages the cognition of T2DM patients very early. Objective: We aimed to investigate the role and potential clinical value of Nampt in early cognitive decline of T2DM. Methods: A total of 195 Chinese T2DM patients were enrolled and divided into a mild cognition impairment (MCI) group and a healthy cognition group according to Montreal Cognitive Assessment (MoCA) score. Their cognitive function was extensively assessed. The plasma level of Nampt was measured via enzyme-linked immunosorbent assay. Results: In the MCI group ( n = 78, MoCA < 26), the plasma level of Nampt was significantly higher than the controls ( p < 0.01). After adjusting for age, sex, and level of education, Nampt levels were negatively associated with most of the cognitive domains forecasting hypomnesia (all p < 0.007). Nevertheless, hierarchical regression analysis further revealed that Nampt was an independent risk factor of MCI in Chinese T2DM patients (all p < 0.05), including Logic Memory Test (β= –0.31, p < 0.01), Auditory Verbal Learning Test delayed recall (β= –0.26, p < 0.01), and so on, which represent memory function. Correlation analysis showed that Nampt related to insulin resistance (HOMA-IR), glycosylated hemoglobin (HbA1c), and lipid levels (all p < 0.05). Conclusions: We found that higher plasma level of Nampt presages memory dysfunction in MCI in Chinese T2DM patients. Further studies are necessary to confirm its scanning and prognosis prediction value of the disease clinically.Keywords
This publication has 37 references indexed in Scilit:
- Type 2 Diabetes and Cognitive CompromiseEndocrinology and Metabolism Clinics of North America, 2013
- Nicotinamide Phosphoribosyltransferase May Be Involved in Age-Related Brain DiseasesPLOS ONE, 2012
- Visfatin in overweight/obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases: a meta‐analysis and systemic reviewDiabetes/Metabolism Research and Reviews, 2011
- Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1‐dependent adenosine monophosphate–activated kinase pathwayAnnals of Neurology, 2011
- A novel pathway regulates memory and plasticity via SIRT1 and miR-134Nature, 2010
- Epigenetic oxidative redox shift (EORS) theory of aging unifies the free radical and insulin signaling theoriesExperimental Gerontology, 2010
- The relationship of visfatin/pre–B-cell colony-enhancing factor/nicotinamide phosphoribosyltransferase in adipose tissue with inflammation, insulin resistance, and plasma lipidsMetabolism, 2010
- Relationship Between Cerebrospinal Fluid Visfatin (PBEF/Nampt) Levels and Adiposity in HumansDiabetes, 2009
- Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosisClinical Endocrinology, 2008
- The cholinergic hypothesis of Alzheimer's disease: a review of progressJournal of Neurology, Neurosurgery & Psychiatry, 1999